PD-1 and PD-1 ligands: from discovery to clinical application
The DOI matches its Crossref record; 133 of the 138 references it cites were found in a registry or an index.
Abstract
Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. Because of the wide range of ligand distribution in the body, its biological significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege. In this review, we would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clinical application of PD-1 agonists and antagonists to various human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 interacts with an SHP2 tyrosine phosphatase domain, leading to dephosphorylation of signaling molecules downstream of the TCR and inhibiting TCR-mediated activation of IL2 production and T-cell proliferation (13).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Nguyen, L. T., Radhakrishnan, S., Ćirić, B., Tamada, K., Shin, T., Pardoll, D. M., Chen, L., Rodriguez, M., & Pease, L. R. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021466 · Cited by 105 · cited 1×
“However, one group reported that cross-linking of PD-L2 induces stimulatory signal in dendritic cells (DCs), resulting in the augmented antigen presentation ( 26 , 27).”
BackgroundRetractedRadhakrishnan, S., Nguyen, L. T., Ćirić, B., Ure, D., Zhou, B., Tamada, K., Dong, H., Tseng, S.-Y., Shin, T., Pardoll, D. M., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.4.1830 · Cited by 73
RetractedFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Self-citationTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Self-citation
Cited by
Items 501–600 of 1,001
CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review
Khan, E. I., Shrestha, A. K., Elkhooly, M., Wilson, H. E., Ebbert, M., Srivastava, S., Wen, S., Rollins, S., & Sriwastava, S. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120089 · Cited by 37
Inaba, H., Kaido, Y., Ito, S., Hirobata, T., Inoue, G., Sugita, T., Yamamoto, Y., Jinnin, M., Kimura, H. J., Kobayashi, T., et al. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1282 · Cited by 34
“Immune-checkpoint inhibitors (ICIs) are effective agents in cancer immunotherapy [1,2].”
Chapter 5 Dysregulation of T Cell Peripheral Tolerance in Type 1 Diabetes
Tisch, R., & Wang, B. (2008) · Advances in immunology · doi:10.1016/s0065-2776(08)00805-5 · Cited by 37
Frazier, A. D., Zhang, C. L., Ni, L., Cheng, J., Zhang, Y., Wu, X. Y., Atia, A. N., Yao, Z. Q., & Moorman, J. P. (2010) · Viral Immunology · doi:10.1089/vim.2010.0010 · Cited by 31
Vitamin D increases programmed death receptor-1 expression in Crohn’s disease
Bendix, M., Greisen, S. R., Dige, A. K., Hvas, C. L., Fuglsang, N. F. B., Jørgensen, S. P., Dahlerup, J. F., Deleuran, B. W., & Agnholt, J. S. (2017) · Oncotarget · doi:10.18632/oncotarget.15489 · Cited by 32
“com/oncotarget By this way, PD-1 serves to hinder auto-reactive T cell responses [15].”
BackgroundHe, H., Qi, X., Fu, H., Xu, J., Zheng, Q., Chen, L., Zhang, Y., Hua, H., Xu, W., Xu, Z., et al. (2023) · Theranostics · doi:10.7150/thno.87243 · Cited by 30
“After activation, T cells express PD-1 receptor molecules on the membrane surface and produce interferons, which can also induce the expression of PD-L1 in tissues (including tumors) [32-35].”
BackgroundMahmoudi, M., Rezaiemanesh, A., Salmaninejad, A., Harsini, S., Poursani, S., Bahrami, T., Tahghighi, F., Ziaee, V., & Rezaei, N. (2015) · Autoimmunity · doi:10.3109/08916934.2015.1058370 · Cited by 34
“More than 30 SNPs have currently been distinguished in the human PDCD1 gene, several of which have been associated with susceptibility to autoimmunity in different ethnicities [26].”
BackgroundAdaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications
Fatourou, E. M., & Koskinas, J. S. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.103 · Cited by 35
Castella, B., Foglietta, M., Riganti, C., & Massaia, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01492 · Cited by 31
Hao, J., Li, M., Zhang, T., Yu, H., Liu, Y., Xue, Y., An, R., & Wang, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00614 · Cited by 32
“The programmed cell death protein 1 (PD-1) is an immunoinhibitory receptor expressed on activated CD4+ and CD8+ TILs that, together with its ligands PD-L1 and PD-L2 that are expressed in tumor cells, helps to negatively regulate TILs activation (53, 54).”
BackgroundNon-Coding RNA and Immune-Checkpoint Inhibitors: Friends or Foes?
Shek, D., Read, S. A., Akhuba, L. G., Qiao, L., Gao, B., Nagrial, A. M., Carlino, M. S., & Ahlenstiel, G. (2020) · Immunotherapy · doi:10.2217/imt-2019-0204 · Cited by 33
Advances in Screening and Development of Therapeutic Aptamers Against Cancer Cells
Li, Z., Fu, X., Huang, J., Zeng, P., Huang, Y., Chen, X., & Liang, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.662791 · Cited by 41
New insights into the important roles of tumor cell-intrinsic PD-1
Zheng, H., Ning, Y., Zhan, Y., Liu, S., Wen, Q., & Fan, S. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.60114 · Cited by 31
“are important structural sites for PD-1 to exert immunosuppressive effect [13, 14].”
BackgroundEmerging antibody combinations in oncology
Demarest, S. J., Hariharan, K., & Dong, J. (2011) · mAbs · doi:10.4161/mabs.3.4.16615 · Cited by 32
Narumi, Y., Isomoto, H., Shiota, M., Sato, K., Kondo, S., Machida, H., Yanagihara, K., Mizuta, Y., Kohno, S., & Tsukamoto, K. (2009) · Journal of Clinical Immunology · doi:10.1007/s10875-008-9272-6 · Cited by 34
“As another immunoreceptor of the CD28/CTLA4 family, programmed cell death 1 (PD-1) is also expressed on T cells, as well as B cells and myeloid cells.”
BackgroundInfluentialStructure and function of programmed death (PD) molecules
Folkl, A., & Bienzle, D. (2009) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2009.10.006 · Cited by 35
Immunomodulation in hepatocellular cancer
Lee, S., Loecher, M., & Iyer, R. V. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.06.08 · Cited by 33
“CTLA-4 and PD-1 systems help prevent overstimulation of immune responses to both foreign and self-antigens (42-44).”
BackgroundGodiyal, Y., Maheshwari, D., Taniguchi, H., Zinzuwadia, S. S., Díaz, Y. M., Tewari, D., & Bishayee, A. (2024) · Military Medical Research · doi:10.1186/s40779-024-00586-9 · Cited by 52
Bayram, S., Akkız, H., Ülger, Y., Bekar, A., Akgöllü, E., & Yıldırım, S. (2012) · Gene · doi:10.1016/j.gene.2012.09.119 · Cited by 28
Endocrine sequelae of immune checkpoint inhibitors
Ntali, G., Kassi, E. N., & Alevizaki, M. K. (2017) · HORMONES · doi:10.14310/horm.2002.1754 · Cited by 32
Edahiro, R., Kanazu, M., Kurebe, H., Mori, M., Fujimoto, D., Taniguchi, Y., Suzuki, H., Hirano, K., Yokoyama, T., Morita, M., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220570 · Cited by 29
NK Cell-Fc Receptors Advance Tumor Immunotherapy
Sanseviero, E. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101667 · Cited by 34
Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors
Duong, S. L., & Prüss, H. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01184-0 · Cited by 35
Deficiency of the CD155-CD96 immune checkpoint controls IL-9 production in giant cell arteritis
Ohtsuki, S., Wang, C., Watanabe, R., Zhang, H., Akiyama, M., Bois, M. C., Maleszewski, J. J., Warrington, K. J., Berry, G. J., Goronzy, J. J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101012 · Cited by 33
Kanazu, M., Edahiro, R., Krebe, H., Nishida, K., Ishijima, M., Uenami, T., Akazawa, Y., Yano, Y., Yamaguchi, T., & Mori, M. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12894 · Cited by 29
Immune checkpoint blockade therapy for bladder cancer treatment
Kim, J. (2016) · Korean journal of urology · doi:10.4111/icu.2016.57.s1.s98 · Cited by 30
“Recent efforts demonstrated that antibodies blocking the PD-1 and PD-L1 pathway could have anti-tumor effects in the tumor microenvironment [37,38].”
BackgroundIto, F., & Chang, A. E. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.06.005 · Cited by 38
“T-cell coinhibitory receptor with a structure similar to that of CTLA-4 but with a distinct biologic function and ligand specificity.(57,58) PD-1 predominantly regulates effector”
PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer.
Yang, S., Zhang, Q., Liu, S., Wang, A. R., & You, Z. (2016) · Europe PMC (PubMed Central) · Cited by 27
Specenier, P. M. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1249856 · Cited by 31
Immune checkpoint modulators in cancer immunotherapy: Recent advances and combination rationales
Fan, L., Li, Y., Chen, J., Zheng, Y., & Xu, X. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.050 · Cited by 30
Yokobori, T., Yazawa, S., Asao, T., Nakazawa, N., Mogi, A., Sano, R., Kuwano, H., Kaira, K., & Shirabe, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-51021-2 · Cited by 30
Rochefoucauld, J. D. L., Noël, N., & Lambotte, O. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02295-2 · Cited by 32
García-Fernández, C., Saz, A., Fornaguera, C., & Borrós, S. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00333-5 · Cited by 33
Zhao, Y., Jia, Y., Li, C., Fang, Y., & Shao, R. (2017) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2017.07.002 · Cited by 30
Jennewein, L., Bartsch, G., Gust, K., Kvasnicka, H., Haferkamp, A., Blaheta, R., Mittelbronn, M., Harter, P., & Mani, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8597 · Cited by 27
“Through a complex system of excitatory and inhibitory signals, circulating PD-1-receptor carrying immune cells, like activated CD4+ T cells, CD8+ T cells, natural killer cells, monocytes and B cells, can be activated or inhibited (41).”
Wang, J. C. C., Chen, C., Kundra, A., Kodali, S., Pandey, A., Wong, C., Cheung, T., Gotlieb, V. K., Joseph, G., & Tribie, S. (2019) · Leukemia Research · doi:10.1016/j.leukres.2019.02.010 · Cited by 27
Parry, H., Dowell, A. C., Zuo, J., Verma, K., Kinsella, F. A. M., Begum, J., Croft, W. D., Sharma‐Oates, A., Pratt, G., & Moss, P. A. H. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009349 · Cited by 27
“PD-1 is a member of the CD28 superfamily and is expressed widely on leucocyte populations [1].”
BackgroundBao, Y., Jiang, A., Dong, K., Gan, X., Gong, W., Wu, Z., Liu, B., Bao, Y., Wang, J., & Wang, L. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.62553 · Cited by 35
“Among them, PD-1 is the receptor expressing on T cell surface in PD-1 check-point pathway and is encoded by human PDCD1 gene [25, 26].”
BackgroundMultifunctional Nanosystems Powered Photodynamic Immunotherapy
Ma, Y., Xiao, F., Lu, C., & Wen, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.905078 · Cited by 28
Sari, M. I., & Ilyas, S. (2022) · Diagnostics · doi:10.3390/diagnostics12082004 · Cited by 27
Small molecule agents for triple negative breast cancer: Current status and future prospects
Ou, Y., Wang, M., Xu, Q., Sun, B., & Jia, Y. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101893 · Cited by 31
“It inhibits T cell activation by interacting with Programmed cell death-Ligand 1 (PD-L1) or Pro-grammed cell death-Ligand 2 (PD-L2) to enable immune evasion of tumor cells [248].”
BackgroundAdvanced gastric adenocarcinoma: optimizing therapy options
Kaya, D. M., Harada, K., Shimodaira, Y., Amlashi, F. G., Lin, Q. D., & Ajani, J. A. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1279969 · Cited by 26
Wolford, J. E., & Tewari, K. S. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1443074 · Cited by 27
“Consequently, the tumor cells exploit the PD-1/PD-L1 system to protect itself from the cytotoxic T-cells by deactivating the cytotoxic T-cells and preventing the activation of new T-cells, suppressing the immune response [25,29,30].”
BackgroundJia, Y., Zhao, Y., Li, C., & Shao, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159383 · Cited by 26
“PD-1 can effectively inhibit functioning and proliferation of the T cells, and reduce IL-2, IL-10 and IFN-γ secretion [6,7], playing an important role in immune regulation [8].”
BackgroundKato, K., Doki, Y., Ura, T., Hamamoto, Y., Kojima, T., Tsushima, T., Hironaka, S., Hara, H., Kudo, T., Iwasa, S., et al. (2020) · Cancer Science · doi:10.1111/cas.14380 · Cited by 26
Damage-associated molecular patterns and Toll-like receptors in the tumor immune microenvironment
Yanai, H., Hangai, S., & Taniguchi, T. (2021) · International Immunology · doi:10.1093/intimm/dxab050 · Cited by 31
Immune checkpoint blockade therapy: The 2014 Tang prize in biopharmaceutical science
Shen, C., & Chen, Y.-S. (2015) · Biomedical Journal · doi:10.4103/2319-4170.151150 · Cited by 30
“programmed cell death protein 1 (PD‐1) as im‐ mune inhibitory molecules,([1,2]) which led to their applications in cancer immunotherapy.”
BackgroundSoleimanifar, N., Amirzargar, A. A., Mahmoudi, M., Pourfathollah, A. A., Azizi, E., Jamshidi, A., Rezaei, N., Tahoori, M. T., Bidad, K., Nikbin, B., et al. (2010) · Inflammation · doi:10.1007/s10753-010-9282-4 · Cited by 26
“cytoplasmic domain containing two tyrosine residues located within immunoreceptor tyrosine-based inhibitory and switch motifs (ITIM and ITSM), suggesting that PD-1 is predominantly inhibitory [11, 12].”
Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer
Kim, J. W., Shin, M. S., Kang, Y., Kang, I., & Petrylak, D. P. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.10.010 · Cited by 29
“Upon its engagement with its ligands, programmed death-ligand 1 (PD-L1) or PD-L2, PD-1 negatively regulates T cell receptor signaling and is associated with decreased T cell proliferation and cytokine production, leading to induction of T cell apoptosis and facilitation of T cell anergy and exhaustion.(23,26) PD-1-exp…”
Molecular background of skin melanoma development and progression: therapeutic implications
Olbryt, M. (2019) · Advances in Dermatology and Allergology · doi:10.5114/ada.2019.84590 · Cited by 27
“The previous one is expressed on resting B cells, T cells, macrophages and DCs [64] as well as on various types of tumour cells including melanoma [65].”
BackgroundTargeting the TRIM21-PD-1 axis potentiates immune checkpoint blockade and CAR-T cell therapy
Shi, J., Zhang, Z., Chen, H.-Y., Yao, Y., Ke, S., Yu, K., Shi, J., Xiao, X., He, C., Xiang, B., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.047 · Cited by 31
Davar, D., Socinski, M. A., Đačić, S., & Burns, T. F. (2015) · Experimental Hematology and Oncology · doi:10.1186/s40164-015-0029-7 · Cited by 25
“PD-1/PD-L1 axis constitutes a negative regulatory mechanism by which T-cell activation is homeostatically regulated; but is hijacked by tumors to circumvent effective anti-tumor immunity [4–6].”
Immunotherapy a New Hope for Cancer Treatment: A Review
Rouz, F. N., Shirkhoda, M., Memari, F., Dana, H., Chalbatani, G. M., Mahmoodzad, H., Samarghand, N., Gharagozlo, E., Mohammadi, M. H., Maleki, A. R., et al. (2018) · Pakistan Journal of Biological Sciences · doi:10.3923/pjbs.2018.135.150 · Cited by 27
Roviello, G., D’Angelo, A., Generali, D., Pittacolo, M., Ganzinelli, M., Iezzi, G., de Manzini, N., & Sobhani, N. (2019) · Immunotherapy · doi:10.2217/imt-2019-0011 · Cited by 29
Hicks, R. J., Iravani, A., & Sandhu, S. K. (2019) · PET Clinics · doi:10.1016/j.cpet.2019.08.007 · Cited by 25
Tumor‐derived exosomal PD‐L1 in progression of cancer and immunotherapy
Rasihashemi, S. Z., Rezazadeh‐Gavgani, E., Majidazar, R., Seraji, P., Oladghaffari, M., Kazemi, T., & Lotfinejad, P. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30645 · Cited by 26
“These pathways are inhibited by PD‐1/PD‐L1 interaction and hence, inhibition of T‐cell functions happens (Ghahremanloo et al., 2019; Okazaki & Honjo, 2007).”
BackgroundImmune checkpoint inhibitors in esophageal cancer: Clinical development and perspectives
Nagata, Y., Yamamoto, S., & Kato, K. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2143177 · Cited by 30
PD-1 Regulates the Growth of Human Mastocytosis Cells
Kataoka, T. R., Fujimoto, M., Moriyoshi, K., Koyanagi, I., Ueshima, C., Kono, F., Tsuruyama, T., Okayama, Y., Ra, C., & Haga, H. (2013) · Allergology International · doi:10.2332/allergolint.12-oa-0450 · Cited by 25
Management of advanced hepatocellular carcinoma: review of current and potential therapies
Gomaa, A. I., & Waked, I. A. (2017) · Hepatoma Research · doi:10.20517/2394-5079.2017.03 · Cited by 28
“Blocking the PDL-1PD-1 receptor interaction increases tumor necrosis.([46])”
BackgroundSugita, Y., Furuta, T., Ohshima, K., Komaki, S., Miyoshi, J., Morioka, M., Abe, H., Nozawa, T., Fujii, Y., Takahashi, H., et al. (2017) · Neuropathology · doi:10.1111/neup.12435 · Cited by 25
“naling to immune cells and maintain the immunological state by inhibiting overactivation of host immunity.(1,2) It”
BackgroundCombining immunotherapy with radiation therapy in thoracic oncology
Badiyan, S. N., Roach, M. C., Chuong, M. D., Rice, S. R., Onyeuku, N. E., Remick, J. S., Chilukuri, S. C., Glass, E., Mohindra, P., & Simone, C. B. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.73 · Cited by 26
“The role of PD-1 is to limit the activity of T-cells in peripheral tissues at the time of an inflammatory response to infection in order to minimize autoimmunity (30-36).”
BackgroundClinicopathological analysis of PD-L2 expression in colorectal cancer
Guo, P.-D., Sun, Z., Lai, H.-J., Yang, J., Wu, P., Guo, Y., & Sun, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s177329 · Cited by 27
García-Bates, T. M., Palma, M. L., Shen, C., Gambotto, A. A., Macatangay, B. J. C., Ferris, R. L., Rinaldo, C. R., & Mailliard, R. B. (2018) · Journal of Virology · doi:10.1128/jvi.02035-18 · Cited by 25
“a negative signal to shut down T cell activation (13, 44).”
BackgroundA Subset of CCL25-Induced Gut-Homing T Cells Affects Intestinal Immunity to Infection and Cancer
Fu, H., Jangani, M., Parmar, A., Wang, G., Coe, D., Spear, S., Sandrock, I., Capasso, M., Coles, M. C., Cornish, G. H., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00271 · Cited by 25
Martínez-Salazar, B., Delgado-Domínguez, J., Estrada, J. S., González-Bonilla, C. R., & Becker, I. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.01.016 · Cited by 25
Islam, M. M., Watanabe, E., Salma, U., Ozaki, M., Irahara, T., Tanabe, S., Katsuki, R., Oishi, D., & Takeyama, N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1493214 · Cited by 31
Huang, S., Kang, Y., Liu, T., Xiong, Y., Yang, Z., & Zhang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561968 · Cited by 30
“PD-1 is found on the facet of activated thymocytes while its corresponding ligand, PD-L1 is found on antigen-presenting cells (101, 102).”
Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes
Won, T., Jung, Y. J., Kwon, S. J., Lee, Y. J., Lee, D. I., Min, H., Park, E. S., Joo, S. S., & Hwang, K. W. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1115-3 · Cited by 24
“There are two ligands known to bind to PD-1, which are Programmed death ligand-1 (PD-L1) and Programmed death ligand-2 (PD-L2) (Freeman et al., 2000; Okazaki and Honjo, 2007).”
BackgroundCritical co-stimulatory pathways in the stability of Foxp3+ Treg cell homeostasis in Type I Diabetes
Kornete, M., & Piccirillo, C. A. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.08.007 · Cited by 25
Anti-PD1 and Anti-PD-L1 in the Treatment of Metastatic Melanoma
Simeone, E., Grimaldi, A. M., & Ascierto, P. A. (2015) · Melanoma Management · doi:10.2217/mmt.14.30 · Cited by 27
Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab
Truong, P. V., Rahal, A. K., & Kallail, K. J. (2016) · Cureus · doi:10.7759/cureus.631 · Cited by 24
“Anti-PD-1 works by inhibiting the interaction of PD-1 and PDL-1, thus reversing immune suppression induced by cancer cells [9].”
BackgroundArulraj, T., & Barik, D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206232 · Cited by 29
Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents
Шубникова, Е. В., Букатина, Т. М., Velts, N. Y., Kaperko, D. A., & Кутехова, Г. В. (2020) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2020-8-1-9-22 · Cited by 31
Qiu, J., Tang, W., & Du, C. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009620666200520084415 · Cited by 25
Enhanced Immunotherapeutic Efficacy of Anti–PD-L1 Antibody in Combination with an EP4 Antagonist
Sajiki, Y., Konnai, S., Cai, Z., Takada, K., Okagawa, T., Maekawa, N., Fujisawa, S., Kato, Y., Suzuki, Y., Murata, S., et al. (2020) · ImmunoHorizons · doi:10.4049/immunohorizons.2000089 · Cited by 26
“Programmeddeath (PD)–1 is an immunecheckpointmolecule that negatively regulates T cell function via the interaction with its ligands, PD-ligand 1 (PD-L1) and PD-L2 (1).”
BackgroundLuo, F., Cao, J., Lu, F., Zeng, K., Ma, W., Huang, Y., Zhang, L., & Zhao, H. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02162-w · Cited by 23
Immunomodulatory effects of regorafenib: Enhancing the efficacy of anti-PD-1/PD-L1 therapy
Liu, J., Tao, H., Yuan, T., Li, J., Li, J., Liang, H., Huang, Z., & Zhang, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992611 · Cited by 32
Jeong, T.-J., Lee, H. T., Gu, N., Jang, Y.-J., Choi, S.-B., Park, U. B., Lee, S.-H., & Heo, Y. (2022) · Biomedicines · doi:10.3390/biomedicines10123154 · Cited by 24
“The ligands of PD-1, PD-L1 and PD-L2, are highly expressed in tumor cells, enabling the tumor cells to escape from T-cell immune responses by interacting with PD-1 [4].”
BackgroundXu, L., Zhang, L., Liang, B., Zhu, S., Lv, G., Qiu, L., & Lin, J. (2023) · Pharmaceuticals · doi:10.3390/ph16020213 · Cited by 24
“PD-L1 is PD-1’s major ligand, which can be overexpressed in a variety of malignancies [1].”
Aging‐associated B7‐DC+ B cells enhance anti‐tumor immunity via Th1 and Th17 induction
Tomihara, K., Shin, T., Hurez, V. J., Yagita, H., Pardoll, D. M., Zhang, B., Curiel, T. J., & Shin, T. (2012) · Aging Cell · doi:10.1111/j.1474-9726.2011.00764.x · Cited by 23
“…and in vivo, including the generation of tumor antigen-specific cytotoxic T lympho- cytes (CTLs), which is beneficial to anticancer immune responses (Tseng et al., 2001; Shin et al., 2003, 2005; Matsumoto et al., 2004, 2008; Okazaki & Honjo, 2007; Tsushima et al., 2007; Ishiwata et al., 2010).”
BackgroundMelanoma immunotherapy dominates the field
Diamantopoulos, P. T., & Gogas, H. J. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.06.32 · Cited by 25
The role of PAK4 in the immune system and its potential implication in cancer immunotherapy
Naїja, A., Merhi, M., Inchakalody, V. P., Fernandes, Q., Mestiri, S., Prabhu, K. S., Shahab Uddin, M. S., & Dermime, S. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104408 · Cited by 28
Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors
Li, Z., Wu, X., Zhao, Y., Xiao, Y., Zhao, Y., Zhang, T., Li, H., Sha, F., Wang, Y., Deng, L., et al. (2021) · MedComm · doi:10.1002/mco2.61 · Cited by 23
Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition
Lau, P. K. H., Ascierto, P. A., & McArthur, G. A. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.006 · Cited by 23
Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC
Mann, J., Hoesli, R. C., Michmerhuizen, N. L., Devenport, S. N., Ludwig, M., Vandenberg, T., Matovina, C. N., Jawad, N., Mierzwa, M. L., Shuman, A. M., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17547 · Cited by 25
“As the immunosuppressive function of the PD-1/PD-L1 interaction was revealed and PD-L1 expression was observed in tumor cells, researchers hypothesized that blockade of this pathway could help facilitate eradication of tumors and impede tumor metastasis [20].”
BackgroundThe Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus
Lu, K., Wu, M.-Y., Wang, C., Wang, C., Chung, W., Chung, W., & Chen, C. (2019) · Cells · doi:10.3390/cells8101213 · Cited by 25
“Although polymorphisms at PDCD1 have also been reported to be associated with susceptibility to SLE [98], the clinical efficacy of manipulating this pathway still requires further investigation based on the preclinical studies to date.”
BackgroundWen, B., Zhao, L., Wang, Y., Qiu, C., Xu, Z., Huang, K.-L., Zhu, H., Li, Z., & Li, H. (2019) · Preparative Biochemistry & Biotechnology · doi:10.1080/10826068.2019.1692217 · Cited by 24
“PD-L2 is also been detected in a small number of B-cell lymphomas9.([10]) In the normal”
BackgroundAlbershardt, T. C., Parsons, A. J., Reeves, R. S., Flynn, P., Campbell, D. J., ter Meulen, J., & Berglund, P. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.02.034 · Cited by 24
PD-L1 Expression in Patients with Idiopathic Pulmonary Fibrosis
Kronborg-White, S. B., Madsen, L. B., Bendstrup, E. M., & Poletti, V. E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235562 · Cited by 25
“PD-1 binds to two different ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2), which can be found in a wide variety of cells, including different immune cells and epithelial cells [18,19].”
BackgroundCombination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy
Kiasari, B. A., Abbasi, A., Darestani, N. G., Adabi, N., Moradian, A., Yazdani, Y., Hosseini, G. S., Gholami, N., & Janati, S. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109365 · Cited by 31
Coêlho, M. D. P. S. D. S., Pereira, I. C., de Oliveira, K. G. F., Oliveira, I. K. F., Rizzo, M. D. S., de Oliveira, V. A., da Silva, F. C. C., Torres‐Leal, F. L., & Sousa, J. M. D. C. E. (2022) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2022.11.001 · Cited by 28
Role of epigenetics in OSCC: an understanding above genetics
Vatsa, P. P., Jindal, Y., Bhadwalkar, J., Chamoli, A., Upadhyay, V., & Mandoli, A. (2023) · Medical Oncology · doi:10.1007/s12032-023-01992-0 · Cited by 26
“Immunotherapy agents revolutionized cancer treatment due to their ability to activate the patient immune system to kill tumour cells [100].”
BackgroundPetranović, M., McDermott, S., Mercaldo, S., Little, B. P., Graur, A., Huang, K. B., Fintelmann, F. J., Digumarthy, S. R., & Gainor, J. F. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.08.014 · Cited by 24
Blumenfeld, H., Tohn, R., Haeryfar, S. M. M., Liu, Y., Savage, P. B., & Delovitch, T. L. (2011) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2011.04454.x · Cited by 23
Shepard, M. T., & Bonney, E. A. (2013) · Immunological Investigations · doi:10.3109/08820139.2013.782317 · Cited by 23
“Additionally, more than 30 single nucleotide polymorphisms of the PD-1 gene have been described in humans and some have been linked to autoimmune diseases (Okazaki & Honjo, 2007).”
BackgroundPredictors of Tumor-Infiltrating Lymphocyte Efficacy in Melanoma
Zikich, D., Schachter, J., & Besser, M. J. (2015) · Immunotherapy · doi:10.2217/imt.15.99 · Cited by 24
Mesenchymal Stem Cells Upregulate the Expression of PD-L1 But Not VDR in Dendritic Cells
Moravej, A., Karimi, M. H., Geramizadeh, B., Azarpira, N., Zarnani, A.-H., Yaghobi, R., Khosravi, M., Kalani, M., & Gharesi‐Fard, B. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1225757 · Cited by 23
“Programmed cell death receptor-1 (PD-1) and its ligand (PD-L1) are an example of the negative co-stimulatory molecules (Okazaki & Honjo, 2007; Yamazaki et al., 2002).”
BackgroundOncolytic viruses: emerging options for the treatment of breast cancer
Suryawanshi, Y. R., Zhang, T., & Essani, K. (2017) · Medical Oncology · doi:10.1007/s12032-017-0899-0 · Cited by 23
“well as secondary metastatic sites [76, 77].”
Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors
Franzese, O., Torino, F., Fuggetta, M. P., Aquino, A., Roselli, M., Bonmassar, E., Giuliani, A., & D’Atri, S. (2017) · Oncotarget · doi:10.18632/oncotarget.16335 · Cited by 23
“The two ligands for PD-1 are PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273) [109, 113-115].”
Origin of biomolecular games: deception and molecular evolution
Massey, S. E., & Mishra, B. (2018) · Journal of The Royal Society Interface · doi:10.1098/rsif.2018.0429 · Cited by 23
Metadata
- Authors
- Okazaki, T., & Honjo, T.
- Affiliations
- Kyoto University (JP)
- ORCID
- Okazaki, T.
- Venue
- International Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06-22
- Volume
- 19
- Issue
- 7
- Pages
- 813-824
- ISSN
- 0953-8178 (ISSN-L)
- 1460-2377
- OpenAlex
- W2122639773
- Cited by
- 1,310
- References
- 138
- Citations by year
- 2026: 26 · 2025: 53 · 2024: 96 · 2023: 94 · 2022: 100 · 2021: 125 · 2020: 152 · 2019: 101 · 2018: 100 · 2017: 112 · 2016: 72 · 2015: 70 · 2014: 41 · 2013: 48 · 2012: 29
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Biomedical Innovation
- Japan Society for the Promotion of Science (17047024, 19689012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, PD-L1, PD-L2, immune checkpoint, SHP2, autoimmunity, antitumor immunity, transplantation immunity, allergy, immune privilege, clinical application
- MeSH terms
- Animals, Autoimmune Diseases, Humans, Immunity, Ligands, Antigens, CD, Intercellular Signaling Peptides and Proteins, Mice, B7-H1 Antigen, Programmed Cell Death 1 Ligand 2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.